Cyclacel Pharmaceuticals announced the award of a grant of approximately $1.9M from the UK Government's Biomedical Catalyst to complete IND-directed preclinical development of CYC065, its novel, orally available, second generation, cyclin-dependent kinase, or CDK, inhibitor. The project aims to complete IND-directed preclinical development of CYC065 and following regulatory clearance enable first-in-humans Phase 1 clinical studies. A key component of the project is a translational biology effort which may lead to validating one or more patient stratification biomarkers. Such biomarkers will be used to inform clinical development of CYC065 and direct its administration to patient groups most likely to benefit from the drug's mechanism.
- Pharmaceuticals & Drug Trials